跳至主要内容
临床试验/NCT06099067
NCT06099067已完成不适用

Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus

AstraZeneca1 个研究点 分布在 1 个国家目标入组 239,990 人开始时间: 2020年5月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
239,990
试验地点
1
主要终点
3-point MACE

研究概览

简要总结

Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.

详细描述

RCT-duplicate (RCT-D) is an initiative led by the Brigham and Women's Hospital and Harvard Medical School, that selected 30 clinical trials as part of an empirical experiment where these trials would be emulated using RWD. AstraZeneca will replicate three emulations CANVAS, LEADER, and SAVOR TIMI from among the 30 plus clinical trials analyzed in RCT-D. These clinical trials assess type 2 diabetes mellitus drugs. The replications will be conducted on the Instant Health Data PANALGOS (IHD) platform to assess these studies in two claims databases Optum and IBM Watson Market Scan. The aim is to recreate these three emulations to investigate the reproducibility of the emulations, increase transparency and better understand the process of trial emulations; and where possible, contribute with potential improvements to the RCT-D framework.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

CANVAS Canagliflozin

CANVAS expousre Group

干预措施: Canagliflozin (Drug)

CANVAS DPP4i

CANVAS reference Group

干预措施: DPP4 inhibitor (Drug)

LEADER Liraglutide

LEADER exposure Group

干预措施: Liraglutide (Drug)

LEADER DPP4i

LEADER reference Group

干预措施: DPP4 inhibitor (Drug)

SAVOR-TIMI Saxagliptin

SAVOR-TIMI exposure Group

干预措施: Saxagliptin (Drug)

SAVOR-TIMI 2nd generation Sulfonylurea

SAVOR-TIMI reference Group

干预措施: 2nd generation Sulfonylurea (Drug)

结局指标

主要结局

3-point MACE

时间窗: Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days]

3-point MACE: Relative hazard of composite outcome of Stroke, MI, and Mortality

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验